4//SEC Filing
GOODMAN COREY S 4
Accession 0000905148-23-000957
CIK 0001825367other
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 4:30 PM ET
Size
21.9 KB
Accession
0000905148-23-000957
Insider Transaction Report
Form 4
RayzeBio, Inc.RYZB
Transactions
- Conversion
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total→ Common Stock (247,343 underlying) - Conversion
Common Stock
2023-09-19+247,343→ 5,158,162 total - Conversion
Common Stock
2023-09-19+1,123,862→ 4,910,819 total - Conversion
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total→ Common Stock (3,786,957 underlying) - Conversion
Common Stock
2023-09-19+3,786,957→ 3,786,957 total - Conversion
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total→ Common Stock (1,123,862 underlying)
VENBIO GLOBAL STRATEGIC GP III, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2023-09-19+3,786,957→ 3,786,957 total - Conversion
Common Stock
2023-09-19+1,123,862→ 4,910,819 total - Conversion
Common Stock
2023-09-19+247,343→ 5,158,162 total - Conversion
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total→ Common Stock (3,786,957 underlying) - Conversion
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total→ Common Stock (1,123,862 underlying) - Conversion
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total→ Common Stock (247,343 underlying)
GOODMAN COREY S
10% Owner
Transactions
- Conversion
Common Stock
2023-09-19+3,786,957→ 3,786,957 total - Conversion
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total→ Common Stock (1,123,862 underlying) - Conversion
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total→ Common Stock (3,786,957 underlying) - Conversion
Common Stock
2023-09-19+1,123,862→ 4,910,819 total - Conversion
Common Stock
2023-09-19+247,343→ 5,158,162 total - Conversion
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total→ Common Stock (247,343 underlying)
VENBIO GLOBAL STRATEGIC GP III, LTD
10% Owner
Transactions
- Conversion
Common Stock
2023-09-19+1,123,862→ 4,910,819 total - Conversion
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total→ Common Stock (1,123,862 underlying) - Conversion
Common Stock
2023-09-19+3,786,957→ 3,786,957 total - Conversion
Common Stock
2023-09-19+247,343→ 5,158,162 total - Conversion
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total→ Common Stock (3,786,957 underlying) - Conversion
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total→ Common Stock (247,343 underlying)
Adelman Robert J
10% Owner
Transactions
- Conversion
Common Stock
2023-09-19+3,786,957→ 3,786,957 total - Conversion
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total→ Common Stock (1,123,862 underlying) - Conversion
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total→ Common Stock (3,786,957 underlying) - Conversion
Common Stock
2023-09-19+1,123,862→ 4,910,819 total - Conversion
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total→ Common Stock (247,343 underlying) - Conversion
Common Stock
2023-09-19+247,343→ 5,158,162 total
Footnotes (4)
- [F1]Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date.
- [F2]Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
- [F3]Each share of Series C Convertible Preferred Stock (the "Series C Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date.
- [F4]These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein.
Documents
Issuer
RayzeBio, Inc.
CIK 0001825367
Entity typeother
Related Parties
1- filerCIK 0001278411
Filing Metadata
- Form type
- 4
- Filed
- Sep 20, 8:00 PM ET
- Accepted
- Sep 21, 4:30 PM ET
- Size
- 21.9 KB